Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Top Alliance
Rockville, Maryland, United Statesjunshipharma.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
TopAlliance Biosciences is a clinical-stage biopharmaceutical company and the North American research and development arm of Shanghai Junshi Biosciences. The company focuses on the discovery and development of innovative therapies, particularly in oncology, metabolic diseases, and inflammation. Its flagship product, Loqtorzi (toripalimab), is a PD-1 inhibitor that has received FDA approval for the treatment of recurrent or metastatic nasopharyngeal carcinoma. TopAlliance manages a diverse pipeline of monoclonal antibodies and other biologics, leveraging its global R&D infrastructure to bring novel treatments to the US and international markets.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateSmall molecule
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Top Alliance.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Top Alliance.